Patient Portal

New Medicare GLP 1 Bridge Program

This program is designed to help patients safely begin GLP-1 weight management therapy while providing the close medical supervision necessary for the best possible outcomes.

Important Program Information

Initial Consultation Required
If you are interested in starting GLP-1 therapy, you must schedule a dedicated office visit to discuss your weight loss goals, medical history, and determine if this treatment is appropriate for you.

Monthly Follow-Up Visits (First 4 Months)
During the course of your treatment, monthly office visits are required. These visits allow your provider to:

  • Monitor your progress and weight loss
  • Evaluate any side effects
  • Determine whether your medication dosage should be adjusted
  • Decide whether a refill is appropriate

No Office Visit = No Refill
To ensure your safety and the effectiveness of your treatment, we will be implementing a “No Office Visit, No Refill” policy.

Prescription Processing

We anticipate significant interest in the GLP-1 Bridge Program, and participating pharmacies may experience a high volume of prescription requests.

Please allow at least one week after your prescription is sent for your medication to be processed and ready for pickup.

We appreciate your patience and understanding as we work to provide safe, effective, and individualized care for every patient.

If you have questions or would like to schedule your initial consultation, please contact our office.

New for Medicare Beneficiaries:

Access to Obesity Medications for Eligible Medicare Beneficiaries

Program Dates: July 1, 2026 through December 31, 2027

A temporary CMS program designed to improve access to evidence-based obesity care while CMS gathers more data before any future Part D Balance model rollout.

Who is Eligible?

You must be enrolled in a Medicare Part D plan:

  • Standalone Medicare Part D Prescription Drug Plan (PDP)
  • Medicare Advantage Plan that includes Part D (MA-PD)

IMPORTANT TO KNOW:

Coverage is based on your BMI at the time GLP-1 therapy was initiated, not at the time of approval.

CLNICAL QUALIFICATION CRITERIA

Must be prescribed for reduction of excess body weight and maintenance of weight reduction in combination with current and ongoing lifestyle modification (nutrition and physical activity).

BMI ≥ 35

Age 18 or older and BMI ≥ 35 at the time GLP-1 therapy was initiated.

BMI ≥ 30 

Plus one of the following:

  • Heart failure with Preserved Ejection Fraction (HFpEF)
  • Uncontrolled Hypertension
  • Chronic Kidney Disease (CKD) Stage 3a or above

BMI ≥ 27

Pluse one of the following:

  • Prediabetes
  • Previous Myocardial Infarction (MI)
  • Previous stroke
  • Symptomatic Peripheral Artery Disease (PAD)

Covered Medications

Eligible GLP-1 medications for obesity Include:

  • Wegovy (injection adn tablets)
  • Foundayo
  • Zepbound KwikPen (KwikPen Only)

Patient Cost

$50 Per Monthly Supply

  • Not subject to Part D deductible
  • Copay stays the same regardless of Part D phase
  • Does not count toward Part D out-of-pocket costs

How It Works;

  • Provider submits a prior authorization request attesting criteria are met
  • Provider sends eligible prescription to the pharmacy
  • Pharmacy processes claim through CMS GLP-1 Bridge.